Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Corey

Showing results (201-210 of 222) with videos related to

Pageof 23
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2024
Small-molecule disruption of androgen receptor-dependent chromatin clustersSarah E Kohrt, Emily J Novak, Subhashish Tapadar, et al.
NPJ Precision Oncology|May 17, 2024
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlatesAzra Ajkunic, Erolcan Sayar, Martine P Roudier, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2025
Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancerSamuel P Pitzen, Amber N Rudenick, Yinjie Qiu, et al.
Nature Communications|May 28, 2025
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stressAndreas Varkaris, Keshan Wang, Mannan Nouri, et al.
The Journal of Pathology|October 18, 2023
Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancerRadhika A Patel, Erolcan Sayar, Ilsa Coleman, et al.
Cell Reports. Medicine|July 3, 2025
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancerTesa M Severson, Emma Minnee, Yanyun Zhu, et al.
Cell Reports. Medicine|January 20, 2024
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomasShiqin Liu, Timothy Chai, Fernando Garcia-Marques, et al.
Nature Communications|May 13, 2022
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targetsXintao Qiu, Nadia Boufaied, Tarek Hallal, et al.
Molecular Cancer Therapeutics|August 2, 2018
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate CancerSong Cho, Francesca Zammarchi, David G Williams, et al.
The Prostate|August 4, 2018
Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) modelsNora M Navone, Wytske M van Weerden, Robert L Vessella, et al.
Pageof 23

Showing results (201-210 of 222) with videos related to

Sort By:
Pageof 23
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2024
Small-molecule disruption of androgen receptor-dependent chromatin clustersSarah E Kohrt, Emily J Novak, Subhashish Tapadar, et al.
NPJ Precision Oncology|May 17, 2024
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlatesAzra Ajkunic, Erolcan Sayar, Martine P Roudier, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2025
Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancerSamuel P Pitzen, Amber N Rudenick, Yinjie Qiu, et al.
Nature Communications|May 28, 2025
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stressAndreas Varkaris, Keshan Wang, Mannan Nouri, et al.
The Journal of Pathology|October 18, 2023
Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancerRadhika A Patel, Erolcan Sayar, Ilsa Coleman, et al.
Cell Reports. Medicine|July 3, 2025
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancerTesa M Severson, Emma Minnee, Yanyun Zhu, et al.
Cell Reports. Medicine|January 20, 2024
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomasShiqin Liu, Timothy Chai, Fernando Garcia-Marques, et al.
Nature Communications|May 13, 2022
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targetsXintao Qiu, Nadia Boufaied, Tarek Hallal, et al.
Molecular Cancer Therapeutics|August 2, 2018
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate CancerSong Cho, Francesca Zammarchi, David G Williams, et al.
The Prostate|August 4, 2018
Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) modelsNora M Navone, Wytske M van Weerden, Robert L Vessella, et al.
Pageof 23